Why Does PrEP Use Lag in Cisgender Women?
How will new study results inform HIV prevention in the US and globally? JAMA Deputy Editor Preeti Malani, MD, MSJ, and author Jeanne Marrazzo, MD, MPH, director of NIAID, discuss these study findings and more. Related Content: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - March 1, 2024 Category: General Medicine Authors: JAMA Network Source Type: podcasts
In MODERN Trial, Maraviroc Inferior to Tenofovir/FTC
Dr. Paul Sax reviews results of the MODERN trial presented at AIDS 2014, which compared maraviroc with tenofovir/FTC in treatment-naive patients. (Source: Medscape Infectious Disease Podcast)
Source: Medscape Infectious Disease Podcast - September 5, 2014 Category: Infectious Diseases Authors: Medscape Source Type: podcasts
The Tenofovir Prodrug TAF: Where Do We Stand?
Dr Paul Sax evaluates promising new clinical trial data on a coformulation of emtricitabine/elvitegravir/cobicistat with the tenofovir prodrug TAF. (Source: Medscape HIV AIDS Podcast)
Source: Medscape HIV AIDS Podcast - November 16, 2012 Category: HIV AIDS Authors: Medscape Source Type: podcasts
Top Takeaway From ICAAC 2012: More Good News on Dolutegravir
Dr. Paul Sax reviews data from the SINGLE trial presented at ICAAC 2012 on the benefits of dolutegravir/abacavir/lamivudine vs tenofovir/emtricitabine/efavirenz. (Source: Medscape HIV AIDS Podcast)
Source: Medscape HIV AIDS Podcast - October 19, 2012 Category: HIV AIDS Authors: Medscape Source Type: podcasts
